专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20130071467A1 RETINOID-LIPOSOMES FOR TREATING FIBROSIS 有权
标题翻译：用于治疗纤维化的假体 - 脂质体
公开(公告)号：US20130071467A1
公开(公告)日：2013-03-21
申请号：US13492594
申请日：2012-06-08
申请人： Yoshiro Niitsu , Victor Knopov , Joseph E. Payne , Richard P. Witte , Mohammad Ahmadian , Loren A. Perelman , Violetta Akopian , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nahum , Hagar Kalinski , Igor Mett , Kenjiro Minomi , Wenbin Ying , Yun Liu
发明人： Yoshiro Niitsu , Victor Knopov , Joseph E. Payne , Richard P. Witte , Mohammad Ahmadian , Loren A. Perelman , Violetta Akopian , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nahum , Hagar Kalinski , Igor Mett , Kenjiro Minomi , Wenbin Ying , Yun Liu
IPC分类号： A61K9/127 , A61K31/713
CPC分类号： A61K9/1271 , A61K9/127 , A61K31/713 , C07H21/02 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2320/32 , C12N2320/52
摘要： What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis.
摘要翻译：描述的是包含包含有义链和反义链的双链核酸分子的药物组合物，其中有义链和反义链选自描述为SERPINH1_2的寡核苷酸（SEQ ID NO：60和127），SERPINH1_45a（SEQ ID NO： NOS：98和165）和SERPINH1_51（SEQ ID NO：101和168）和包含类视黄醇和脂质囊泡的混合物的药物载体，以及使用这些药物组合物治疗与hsp47表达相关的疾病的方法，包括纤维化。

52. 发明申请

US20120136044A1 Compositions And Methods Of Inhibiting NADPH Oxidase Expression 审中-公开
标题翻译：抑制NADPH氧化酶表达的组成和方法
公开(公告)号：US20120136044A1
公开(公告)日：2012-05-31
申请号：US13368064
申请日：2012-02-07
申请人： Hagar Kalinski , Igor Mett , Elena Feinstein
发明人： Hagar Kalinski , Igor Mett , Elena Feinstein
IPC分类号： A61K31/713 , A61P27/16 , A61P13/12 , A61P17/00 , A61P11/00 , A61P37/06 , A61P25/00 , A61P19/02 , C07H21/02 , A61P27/02
CPC分类号： C12N15/1137 , A01K67/027 , A01K2207/05 , A01K2207/10 , A01K2207/20 , A01K2207/30 , A01K2227/105 , A01K2267/03 , A01K2267/0368 , C12N2310/14
摘要： The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of a NOX gene selected from the group consisting of NOX4, NOX1, NOX2 (gp91phox, CYBB), NOX5, DUOX2, NOXO1, NOXA1 and NOXA2 (p67phox). The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of various diseases or conditions associated with NOX gene comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
摘要翻译：本发明涉及一种或多种抑制剂，特别是siRNA，其下调选自NOX4，NOX1，NOX2（gp91phox，CYBB），NOX5，DUOX2，NOXO1，NOXA1和NOXA2的NOX基因的表达（ p67phox）。本发明还涉及包含化合物或能够表达化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗或预防与NOX基因相关的各种疾病或病症的发生或严重程度的方法，包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。

53. 发明申请

US20110105584A1 RTP80IL SIRNA COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
标题翻译： RTP80IL SIRNA化合物及其使用方法
公开(公告)号：US20110105584A1
公开(公告)日：2011-05-05
申请号：US12735061
申请日：2008-12-11
申请人： Elena Feinstein , Igor Mett , Hagar Kalinski
发明人： Elena Feinstein , Igor Mett , Hagar Kalinski
IPC分类号： A61K31/713 , C07H21/02 , A61P27/16 , A61P27/02 , A61P25/00 , A61P11/00 , A61P9/00 , A61P27/06 , A61P11/06 , A61P9/10 , A61P13/12 , A61P17/00
CPC分类号： C12N15/113 , C12N2310/14
摘要： The invention provides chemically modified siRNA oligonucleotides that target RTP801L, compositions comprising same and to the use of such molecules to treat, inter alia, respiratory diseases including acute and chronic pulmonary disorders, eye diseases including glaucoma and ION, microvascular disorders, angiogenesis- and apoptosis-related conditions, and hearing impairments.
摘要翻译：本发明提供靶向RTP801L的化学修饰的siRNA寡核苷酸，包含其的组合物，以及使用此类分子治疗尤其是呼吸系统疾病，包括急性和慢性肺病，包括青光眼和ION在内的眼睛疾病，微血管病症，血管生成和凋亡相关条件和听力障碍。

54. 发明申请

US20100168204A1 Therapeutic uses of inhibitors of RTP801L 有权
标题翻译： RTP801L抑制剂的治疗用途
公开(公告)号：US20100168204A1
公开(公告)日：2010-07-01
申请号：US12589972
申请日：2009-10-29
申请人： Elena Feinstein , Igor Mett
发明人： Elena Feinstein , Igor Mett
IPC分类号： A61K31/7008 , C07H21/02 , A61P27/00 , A61P9/00 , A61P11/00
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/31 , C12N2310/3521
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.
摘要翻译：本发明提供了基于RTP801L基因和/或蛋白质的抑制来治疗微血管病症，眼睛疾病呼吸系统疾病和听力障碍的新型分子，组合物，方法和用途。

55. 发明申请

US20080249038A1 Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof 审中-公开
标题翻译：骨形态发生蛋白（Bmp）2A及其用途
公开(公告)号：US20080249038A1
公开(公告)日：2008-10-09
申请号：US10575121
申请日：2004-10-06
申请人： Elena Feinstein , Igor Mett , Svetlana Gorodin , Michael Shtutman
发明人： Elena Feinstein , Igor Mett , Svetlana Gorodin , Michael Shtutman
IPC分类号： A61K31/7088 , C07H21/04 , C12N15/00
CPC分类号： C12N15/1136 , C12N2310/11 , C12N2310/111 , C12N2310/14
摘要： The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenerative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
摘要翻译：本发明提供用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是由慢性或急性退行性变化引起。特别地，本发明的一些实施方案提供一种或多种药物组合物，其包含作为活性成分的进一步包含药学上可接受的稀释剂或载体的BMP2A抑制剂。另一个实施方案提供了减轻对中枢神经系统损伤的患者中的中枢神经系统的损伤的方法，包括以足以减少损伤的剂量向患者施用药物组合物。另一个实施方案提供了BMP2A抑制剂用于制备用于促进或增强患有中枢神经系统损伤的患者的恢复的药物的用途。根据本发明一些实施方案的优选的抑制剂是siRNA分子和中和抗体。另外的实施方案提供了鉴定调节细胞凋亡的化合物的方法。此外，提供了用于诊断受试者中的神经变性疾病或缺血事件的方法。现在将要描述的优选方法，材料和实施例仅是说明性的而不是限制性的; 可以在本发明的实践或测试中使用与本文所述类似或等同的材料和方法。从以下详细描述和权利要求书中，本发明的其它特征和优点将变得显而易见。

56. 发明授权

US09205100B2 Compositions and methods for treating lung disease and injury 有权
标题翻译：用于治疗肺部疾病和损伤的组合物和方法
公开(公告)号：US09205100B2
公开(公告)日：2015-12-08
申请号：US14002660
申请日：2012-03-01
申请人： Andrew E. Gelman , Elena Feinstein , Svetlana Adamsky , Igor Mett , Hagar Kalinski , Sharon Avkin-Nachum
发明人： Andrew E. Gelman , Elena Feinstein , Svetlana Adamsky , Igor Mett , Hagar Kalinski , Sharon Avkin-Nachum
IPC分类号： C12N15/11 , A61K31/713 , C12N15/113
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/321 , C12N2310/344 , C12N2310/3521
摘要： Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury.
摘要翻译：本文公开了治疗哺乳动物肺疾病，病症和损伤的治疗方法，包括治疗急性呼吸窘迫综合征（ARDS），急性肺损伤，肺纤维化（特发性），博来霉素诱导的肺纤维化，机械通气机诱导的肺损伤，慢性阻塞性肺疾病（COPD），慢性支气管炎，肺气肿，肺移植后闭塞性细支气管炎和肺移植引起的急性移植物功能障碍，包括治疗，预防或预防原发性移植物衰竭，缺血再灌注损伤，再灌注损伤，再灌注水肿，同种异体移植功能障碍，肺再植入反应，肺移植后闭塞性细支气管炎和/或器官移植后特别是肺移植中的原发性移植物功能障碍（PGD），包括下调TLR2基因或TLR2基因和TLR4基因。本文提供了用于治疗肺部疾病，病症和损伤的组合物，方法和试剂盒。

57. 发明授权

US08710209B2 Modulation of HSP47 expression 有权
标题翻译：调节HSP47表达
公开(公告)号：US08710209B2
公开(公告)日：2014-04-29
申请号：US12963600
申请日：2010-12-08
申请人： Xiaomei Jin , Lei Yu , Hirokazu Takahashi , Yasunobu Tanaka , Yoshiro Niitsu , Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett , Shai Erlich , Elizabeth C. Squiers , Ning Chen
发明人： Xiaomei Jin , Lei Yu , Hirokazu Takahashi , Yasunobu Tanaka , Yoshiro Niitsu , Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett , Shai Erlich , Elizabeth C. Squiers , Ning Chen
IPC分类号： C07H21/04
CPC分类号： C12N15/113 , A61K31/713 , C12N2310/11 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/317 , C12N2310/32 , C12N2310/321 , C12N2310/33 , C12N2310/531 , C12N2320/30 , C12N2310/3521
摘要： Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.
摘要翻译：本文提供用于调节靶基因，特别是热休克蛋白47（hsp47）的表达的组合物，方法和试剂盒。组合物，方法和试剂盒可以包括核酸分子（例如，短干扰核酸（siNA），短干扰RNA（siRNA），双链RNA（dsRNA），微RNA（miRNA）或短发夹RNA（shRNA））），其调节编码hsp47的基因，例如编码人hsp47的基因。本文公开的组合物和方法也可用于治疗与hsp47相关的病症和病症，例如肝纤维化，肺纤维化，腹膜纤维化和肾纤维化。

58. 发明授权

US08664376B2 Retinoid-liposomes for enhancing modulation of HSP47 expression 有权
标题翻译：维甲酸脂质体用于增强HSP47表达的调节
公开(公告)号：US08664376B2
公开(公告)日：2014-03-04
申请号：US13492639
申请日：2012-06-08
申请人： Yoshiro Niitsu , Victor Knopov , Joseph E. Payne , Richard P. Witte , Mohammad Ahmadian , Loren A. Perelman , Violetta Akopian , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nahum , Hagar Kalinski , Igor Mett , Kenjiro Minomi , Wenbin Ying , Yun Liu
发明人： Yoshiro Niitsu , Victor Knopov , Joseph E. Payne , Richard P. Witte , Mohammad Ahmadian , Loren A. Perelman , Violetta Akopian , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nahum , Hagar Kalinski , Igor Mett , Kenjiro Minomi , Wenbin Ying , Yun Liu
IPC分类号： C07H21/04
CPC分类号： A61K9/1271 , A61K9/127 , A61K31/713 , C07H21/02 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2320/32 , C12N2320/52
摘要： What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID NOS: 98 and 165), and SERPINH1—51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.
摘要翻译：所描述的是包含包含有义链和反义链的双链核酸分子的药物组合物，其中有义链和反义链选自描述为SERPINH1-2（SEQ ID NO：60和127）的寡核苷酸，SERPINH1- 45a（SEQ ID NO：98和165）和SERPINH1-51（SEQ ID NO：101和168）和包含类视黄醇和脂质囊泡的混合物的药物载体，以及使用这些药物组合物治疗疾病的方法与hsp47浓缩相关，包括纤维化。

59. 发明申请

US20130137750A1 DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF 有权
标题翻译：双重条纹的RNA化合物和其使用
公开(公告)号：US20130137750A1
公开(公告)日：2013-05-30
申请号：US13700942
申请日：2011-06-23
申请人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
发明人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/113
CPC分类号： C12N15/1135 , C12N15/1137 , C12N2310/14 , C12N2310/141 , C12N2310/321 , C12Q1/6888
摘要： The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.
摘要翻译：本发明涉及化合物，包含其的药物组合物，其使用方法和用于下调RhoA基因的试剂盒。化合物，组合物，方法和试剂盒可用于治疗患有RhoA表达具有不良后果和赋予神经保护作用的疾病或病症和/或与疾病或病症相关的症状的受试者。

60. 发明申请

US20130030034A9 MODULATION OF TIMP1 AND TIMP2 EXPRESSION 审中-公开
标题翻译： TIMP1和TIMP2表达的调控
公开(公告)号：US20130030034A9
公开(公告)日：2013-01-31
申请号：US13246621
申请日：2011-09-27
申请人： Yoshiro Niitsu , Hirokazu Takahashi , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
发明人： Yoshiro Niitsu , Hirokazu Takahashi , Yasunobu Tanaka , Elena Feinstein , Sharon Avkin-Nachum , Hagar Kalinski , Igor Mett
IPC分类号： A61K31/7088 , A61P43/00 , C07H21/02
CPC分类号： C12N15/113 , A61K9/0019 , A61K31/713 , C07K14/8146 , C12N2310/14 , C12N2310/3519 , C12N2320/30 , C12N2320/32
摘要： Provided herein are compositions, methods and kits for modulating expression of target genes, particularly of tissue inhibitor of metalloproteinase 1 and of tissue inhibitor of metalloproteinase 2 (TIMP1 and TIMP2, respectively). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding TIMP1 and TIMP2, for example, the gene encoding human TIMP1 and TIMP2. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with TIMP1 and TIMP2 including fibrotic diseases and disorders including liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.
摘要翻译：本文提供用于调节靶基因，特别是金属蛋白酶1的组织抑制剂和金属蛋白酶2的组织抑制剂（分别为TIMP1和TIMP2）的表达的组合物，方法和试剂盒。组合物，方法和试剂盒可以包括核酸分子（例如，短干扰核酸（siNA），短干扰RNA（siRNA），双链RNA（dsRNA），微RNA（miRNA）或短发夹RNA（shRNA））），其调节编码TIMP1和TIMP2的基因，例如编码人TIMP1和TIMP2的基因。本文公开的组合物和方法也可用于治疗与TIMP1和TIMP2相关的病症和病症，包括纤维化疾病和病症，包括肝纤维化，肺纤维化，腹膜纤维化和肾纤维化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式